Agenus Inc Share Price Today: Live Updates & Key Insights

Agenus Inc share price today is $3.66, up -2.62%. The stock opened at $3.8 against the previous close of $3.81, with an intraday high of $3.8 and low of $3.67.

Agenus Inc Share Price Chart

Agenus Inc

us-stock
To Invest in {{usstockname}}
us-stock

Agenus Inc Share Price Performance

$3.66 -0.0262(-2.62%) AGEN at 23 Mar 2026 11:55 AM Biotechnology
Lowest Today 3.67
Highest Today 3.8
Today’s Open 3.8
Prev. Close 3.81
52 Week High 7.34
52 Week Low 1.38
Day’s Range: Low 3.67 High 3.8
52-Week Range: Low 1.38 High 7.34
1 day return -
1 Week return +12.65
1 month return +20.35
3 month return +4.82
6 month return -19.84
1 year return +125.99
3 year return -87.45
5 year return -94.09
10 year return -

Agenus Inc Institutional Holdings

Vanguard Group Inc 7.83

Siren, L.L.C. 2.94

Vanguard Total Stock Mkt Idx Inv 2.83

Morgan Stanley - Brokerage Accounts 1.52

BlackRock Inc 1.51

Renaissance Technologies Corp 1.50

Vanguard Strategic Equity Inv 1.42

Citadel Advisors Llc 1.17

Geode Capital Management, LLC 1.03

Bank of America Corp 1.02

Vanguard Institutional Extnd Mkt Idx Tr 0.95

Vanguard Explorer Inv 0.80

Susquehanna International Group, LLP 0.65

Millennium Management LLC 0.62

Vanguard Strategic Small-Cap Equity Inv 0.57

Acadian Asset Management LLC 0.57

Vanguard VIF Small Co Gr 0.55

Fidelity Extended Market Index 0.50

Jump Financial LLC 0.47

Panagora Asset Management Inc 0.45

State Street Corp 0.42

Marshall Wace Asset Management Ltd 0.41

D. E. Shaw & Co LP 0.35

Walleye Trading Advisors, LLC 0.34

Acuitas US Microcap Strategy 0.34

Two Sigma Investments LLC 0.32

683 Capital Management LLC 0.32

Man Group PLC 0.32

Blackrock Extended Mkt Fund CF 0.23

iShares Micro-Cap ETF 0.23

Extended Equity Market Fund K 0.20

Fidelity Total Market Index 0.17

Spartan Extended Market Index Pool F 0.13

Fidelity Series Total Market Index 0.13

NT Ext Equity Mkt Idx Fd - L 0.11

Vanguard Market Neutral I 0.09

Northern Trust Extended Eq Market Idx 0.09

Dasc Investments SICAV 0.08

NT Ext Equity Mkt Idx Fd - NL 0.08

Spartan Total Market Index Pool G 0.07

Agenus Inc Market Status

Strong Buy: 1

Buy: 1

Hold: 3

Sell: 0

Strong Sell: 0

Agenus Inc Fundamentals

Market Cap 142.46 M

PB Ratio 218.6149

PE Ratio 0.0

Enterprise Value 195.36 M

Total Assets 226.80 M

Volume 382624

Agenus Inc Company Financials

Annual Revenue FY23:100899000 100.9M, FY22:98024000 98.0M, FY21:295665000 295.7M, FY20:88170000 88.2M, FY19:150048000 150.0M

Annual Profit FY23:-130770000 -130.8M, FY22:-99235000 -99.2M, FY21:113587000 113.6M, FY20:-56796000 -56.8M, FY19:-18291000 -18.3M

Annual Net worth FY23:-270564000 -270.6M, FY22:-271515000 -271.5M, FY21:-94696000 -94.7M, FY20:-240134000 -240.1M, FY19:-149136000 -149.1M

Quarterly Revenue Q3/2025:30235000 30.2M, Q2/2025:25691000 25.7M, Q1/2025:24066000 24.1M, Q3/2024:25112000 25.1M, Q2/2024:23509000 23.5M

Quarterly Profit Q3/2025:5997000 6.0M, Q2/2025:-1262000 -1.3M, Q1/2025:2407000 2.4M, Q3/2024:-16092000 -16.1M, Q2/2024:23394000 23.4M

Quarterly Net worth Q3/2025:63914000 63.9M, Q2/2025:-27955000 -28.0M, Q1/2025:-25266000 -25.3M, Q3/2024:-66386000 -66.4M, Q2/2024:-53081000 -53.1M

About Agenus Inc & investment objective

Company Information Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Organisation Biotechnology

Employees 316

Industry Biotechnology

CEO Dr. Garo H. Armen Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Agenus Inc FAQs

What is the share price of Agenus Inc today?

The current share price of Agenus Inc is $3.66.

Can I buy Agenus Inc shares in India?

Yes, Indian investors can buy Agenus Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Agenus Inc shares in India?

You can easily invest in Agenus Inc shares from India by:

Can I buy fractional shares of Agenus Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Agenus Inc?

Agenus Inc has a market cap of $142.46 M.

In which sector does Agenus Inc belong?

Agenus Inc operates in the Biotechnology sector.

What documents are required to invest in Agenus Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Agenus Inc?

The PE ratio of Agenus Inc is N/A and the PB ratio is 218.61.